Role and Cell Cycle Mechanisms of pp71 in HCMV Infection
pp71在HCMV感染中的作用和细胞周期机制
基本信息
- 批准号:7498688
- 负责人:
- 金额:$ 29.4万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2007
- 资助国家:美国
- 起止时间:2007-09-30 至 2009-09-29
- 项目状态:已结题
- 来源:
- 关键词:AffectAntiviral TherapyAreaBindingBiological AssayCell CycleCell Cycle ProgressionCellsCytomegalovirusCytomegalovirus InfectionsDiseaseEP300 geneEarly Gene TranscriptionsEarly PromotersEventGene ExpressionGenesGeneticGenetic TranscriptionGoalsHomologous GeneHumanImmune responseInterferon ActivationLinkLyticLytic PhaseMacaca mulattaMalignant NeoplasmsMediatingMolecularMolecular GeneticsNatural ImmunityPatientsPhosphorylationPlayPopulationProcessProteinsPublishingRBL2 geneRepressionResearch DesignResistanceRetinoblastoma ProteinRoleTransplantationViralViral ProteinsVirusVirus Diseasesdesignfitnesshuman RBL2 proteinimmune functionlatent infectionlytic replicationmutantpathogenreactivation from latencyrestenosis
项目摘要
Human cytomegalovirus (HCMV) is a significant human pathogen that infects the majority of the world's
population. Primary lytic replication or reactivation of latent infections causes severe disease in patients with
suppressed immune function. Furthermore, many studies link HCMV infection with proliferative diseases
such as cancer, restenosis, and transplant-associated vasculopathy. Because the HCMV pp71 protein
initiates the lytic replication cycle, stimulates cell cycle progression, and may control latency, it is a potential
target for antiviral therapy. We plan to examine the molecular mechanisms behind the different activities of
pp71, and the role that these different activities play during lytic and latent viral replication. We have already
discovered and published the mechanism through which pp71 activates viral immediate early (IE) gene
expression during lytic replication: it degrades the cellular transcriptional represser Daxx. Here we will
generate HCMV mutants that are resistant to Daxx-mediated repression, and use them to further our
understanding of IE gene expression during lytic infection, and determine if the same mechanism applies
during the establishment and/or reactivation of latency. We have previously shown that pp71 stimulates cell
cycle progression by degrading the Rb protein. Here we will examine how pp71 and other viral proteins
cooperate to modulate the activity of Rb (and the related p130 protein) during lytic and latent infections.
Recently, we discovered that pp71 degrades another cellular protein that modulates transcription, the cell
cycle, and innate immunity. Here we will determine how the ability of pp71 to degrade this protein affects
each of those processes in HCMV-infected cells. This proposal builds upon our published and unpublished
discoveries, and will use molecular and genetic approaches to determine not only the mechanisms used by
pp71 to promote viral transcription, induce cell cycle progression, and potentially evade innate immunity, but
also the roles that these activities of pp71 play during both lytic and latent infections. Thus our long-term
goal is to determine the molecular mechanisms behind each function of pp71 in HCMV-infected cells, and
the contribution that the different activities of pp71 make during lytic and latent viral replication cycles. This
information should allow us to design antiviral therapies targeted to the functions of pp71 required for viral
replication to treat both proliferative and non-proliferative diseases associated with HCMV infection.
人巨细胞病毒(HCMV)是一种重要的人类病原体,感染世界上大多数人,
人口原发性裂解性复制或潜伏性感染的再激活导致严重疾病,
抑制免疫功能此外,许多研究将HCMV感染与增殖性疾病联系起来
例如癌症、再狭窄和移植相关血管病变。因为HCMV pp 71蛋白
启动裂解复制周期,刺激细胞周期进程,并可能控制潜伏期,这是一种潜在的
作为抗病毒治疗靶点。我们计划研究不同活动背后的分子机制,
pp 71,以及这些不同的活性在裂解和潜伏病毒复制过程中所起的作用。我们已经
发现并发表了pp 71激活病毒立即早期(IE)基因的机制
在裂解复制过程中表达:它降解细胞转录阻遏物Daxx。这里我们将
产生对Daxx介导的抑制有抗性的HCMV突变体,并使用它们来进一步我们的研究。
了解IE基因在裂解感染过程中的表达,并确定是否适用相同的机制
在等待时间的建立和/或重新激活期间。我们之前已经证明pp 71刺激细胞
通过降解Rb蛋白来抑制细胞周期进程。在这里,我们将研究pp 71和其他病毒蛋白如何
协同调节Rb(和相关的p130蛋白)在裂解和潜伏感染期间的活性。
最近,我们发现pp 71降解另一种调节转录的细胞蛋白,
周期和先天免疫在这里,我们将确定pp 71降解这种蛋白质的能力如何影响
每一个过程都在HCMV感染的细胞中进行。这一建议建立在我们已发表和未发表的
发现,并将使用分子和遗传方法,以确定不仅使用的机制,
pp 71促进病毒转录,诱导细胞周期进程,并可能逃避先天免疫,但
还研究了PP 71的这些活性在溶解性感染和潜伏性感染中所起的作用。我们的长期
目的是确定pp 71在HCMV感染细胞中每种功能背后的分子机制,
PP 71的不同活性在裂解和潜伏病毒复制周期中的作用。这
这些信息应该使我们能够设计针对病毒感染所需的pp 71功能的抗病毒疗法。
复制以治疗与HCMV感染相关的增殖性和非增殖性疾病。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Early apoptosis of macrophages modulated by injection of Yersinia pestis YopK promotes progression of primary pneumonic plague.
- DOI:10.1371/journal.ppat.1003324
- 发表时间:2013
- 期刊:
- 影响因子:6.7
- 作者:Peters KN;Dhariwala MO;Hughes Hanks JM;Brown CR;Anderson DM
- 通讯作者:Anderson DM
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ROBERT F KALEJTA其他文献
ROBERT F KALEJTA的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ROBERT F KALEJTA', 18)}}的其他基金
Deciphering the cell type specific control of HCMV tegument-delivered pp71 subcellular localization
破译 HCMV 皮膜传递的 pp71 亚细胞定位的细胞类型特异性控制
- 批准号:
10176409 - 财政年份:2020
- 资助金额:
$ 29.4万 - 项目类别:
Transcriptional Control of Human Cytomegalovirus Latency
人类巨细胞病毒潜伏期的转录控制
- 批准号:
10370328 - 财政年份:2018
- 资助金额:
$ 29.4万 - 项目类别:
Transcriptional Control of Human Cytomegalovirus Latency
人类巨细胞病毒潜伏期的转录控制
- 批准号:
9894713 - 财政年份:2018
- 资助金额:
$ 29.4万 - 项目类别:
Evading innate immunity during human cytomegalovirus latency
在人类巨细胞病毒潜伏期逃避先天免疫
- 批准号:
9919503 - 财政年份:2018
- 资助金额:
$ 29.4万 - 项目类别:
Transcriptional Control of Human Cytomegalovirus Latency
人类巨细胞病毒潜伏期的转录控制
- 批准号:
9447725 - 财政年份:2018
- 资助金额:
$ 29.4万 - 项目类别:
Evading innate immunity during human cytomegalovirus latency
在人类巨细胞病毒潜伏期逃避先天免疫
- 批准号:
10392335 - 财政年份:2018
- 资助金额:
$ 29.4万 - 项目类别:
Transcriptional Control of Human Cytomegalovirus Latency
人类巨细胞病毒潜伏期的转录控制
- 批准号:
10132969 - 财政年份:2018
- 资助金额:
$ 29.4万 - 项目类别:
Retinoblastoma (Rb) protein pathway in human cytomegalovirus infected cells
人巨细胞病毒感染细胞中的视网膜母细胞瘤 (Rb) 蛋白途径
- 批准号:
8259782 - 财政年份:2010
- 资助金额:
$ 29.4万 - 项目类别:
Retinoblastoma (Rb) protein pathway in human cytomegalovirus infected cells
人巨细胞病毒感染细胞中的视网膜母细胞瘤 (Rb) 蛋白途径
- 批准号:
7984157 - 财政年份:2010
- 资助金额:
$ 29.4万 - 项目类别:
Retinoblastoma (Rb) protein pathway in human cytomegalovirus infected cells
人巨细胞病毒感染细胞中视网膜母细胞瘤 (Rb) 蛋白途径
- 批准号:
8651405 - 财政年份:2010
- 资助金额:
$ 29.4万 - 项目类别:
相似海外基金
Dose Flexible Combination 3D-Printed Delivery Systems for Antiviral Therapy in Children
用于儿童抗病毒治疗的剂量灵活组合 3D 打印输送系统
- 批准号:
10682185 - 财政年份:2023
- 资助金额:
$ 29.4万 - 项目类别:
COVID-19 Immunologic Antiviral therapy with Omalizumab (CIAO trial) - An Adaptive Phase II Randomized-Controlled Clinical Trial
使用奥马珠单抗进行 COVID-19 免疫抗病毒治疗(CIAO 试验)——适应性 II 期随机对照临床试验
- 批准号:
475843 - 财政年份:2022
- 资助金额:
$ 29.4万 - 项目类别:
Studentship Programs
COVID-19 Immunologic Antiviral therapy with Omalizumab (CIAO trial) - An Adaptive Phase II Randomized-Controlled Clinical Trial
使用奥马珠单抗进行 COVID-19 免疫抗病毒治疗(CIAO 试验)——适应性 II 期随机对照临床试验
- 批准号:
474485 - 财政年份:2022
- 资助金额:
$ 29.4万 - 项目类别:
Studentship Programs
Discovery of Bunyaviral Endonuclease Inhibitors for Antiviral Therapy
用于抗病毒治疗的布尼亚病毒核酸内切酶抑制剂的发现
- 批准号:
10481430 - 财政年份:2022
- 资助金额:
$ 29.4万 - 项目类别:
Discovery of Bunyaviral Endonuclease Inhibitors for Antiviral Therapy
用于抗病毒治疗的布尼亚病毒核酸内切酶抑制剂的发现
- 批准号:
10683329 - 财政年份:2022
- 资助金额:
$ 29.4万 - 项目类别:
An interdisciplinary approach towards antiviral therapy discovery
抗病毒疗法发现的跨学科方法
- 批准号:
nhmrc : 1196520 - 财政年份:2021
- 资助金额:
$ 29.4万 - 项目类别:
Investigator Grants
Applying an 'omics' approach to predict hepatic decompensation events and hepatocellular carcinoma in veterans after HCV cure with direct acting antiviral therapy
应用“组学”方法预测退伍军人在使用直接作用抗病毒疗法治愈 HCV 后的肝失代偿事件和肝细胞癌
- 批准号:
10260234 - 财政年份:2021
- 资助金额:
$ 29.4万 - 项目类别:
Applying an 'omics' approach to predict hepatic decompensation events and hepatocellular carcinoma in veterans after HCV cure with direct acting antiviral therapy
应用“组学”方法预测退伍军人在使用直接作用抗病毒疗法治愈 HCV 后的肝失代偿事件和肝细胞癌
- 批准号:
10548114 - 财政年份:2021
- 资助金额:
$ 29.4万 - 项目类别:
Disparities in the Diffusion of Direct-Acting Antiviral Therapy for Hepatitis C among Baby Boomers: A Mixed-Methods Study
婴儿潮一代丙型肝炎直接作用抗病毒疗法传播的差异:一项混合方法研究
- 批准号:
10400318 - 财政年份:2020
- 资助金额:
$ 29.4万 - 项目类别:
Development of novel antiviral therapy targeting hepatitis B virus host restriction factor
针对乙型肝炎病毒宿主限制因子的新型抗病毒疗法的开发
- 批准号:
20K08371 - 财政年份:2020
- 资助金额:
$ 29.4万 - 项目类别:
Grant-in-Aid for Scientific Research (C)